Ovid is actively evaluating its pipeline and undertaking an ongoing process to review indication and development strategies. As part of this process, the Company has currently focused resources on advancing OV888/GV101 and OV329 oral programs toward significant clinical milestones. It also paused the intravenous OV329 program and other preclinical programs.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OVID:
- Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
- Ovid Therapeutics appoints Banks as Chief Development Officer
- OVID Earnings this Week: How Will it Perform?
- Ovid Therapeutics Announces Leadership Transition and Consulting Deal
- Ovid Therapeutics to Present at Upcoming August Investor Conferences